FDA MAP
  • Home
  • Training
    • WORKSHOPS
    • WEBINARS
    • CUSTOM TRAINING
  • SERVICES
    • REGULATORY SERVICES
    • FDA AUDITING
    • QUALITY ASSURANCE
    • CLINICAL TRIAL SERVICES
  • News Releases
  • About Us
Newsletter - September 7, 2017
​
The Practical Implications of FDA and EMA Sharing Confidential GMP Information  
 ​
FDA and EMA signed a mutual confidentiality arrangement this month which commits both agencies to share all information about manufacturing operations located in either region including trade secret and non-public information. The agreement will become effective on 1 Nov 2017 and will be in transition phase till July 2019 giving both agencies time to work out any issues due to the arrangement. Read More

FDA Explains What is Real World Evidence and How It Can Be Used 

Real World Evidence (RWE) and Real World Data (RWD) are very important but distinct aspects of the clinical use information available for a drug. The 21st Century Cures Act mandates FDA to use RWE in support of the approval of a product and FDA’s opinion about the utility of such data in support of market approval is evolving rapidly. Read More

Our Services

  • Workshops
  • Webinars
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions
  • Corporate Registration
  • Certification Program
  • Smart Recruitment
  • Corporate Registration - Online Workshop​

Company

  • About Us​
  • Testimonials
  • Free Resources
  • Newsletter
  • Videos (Free Tutorials)

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy
  • News Archive
Consultation Service
FDA Training Company
Copyright © 2023 FDAMap.com
Use of this Web site constitutes acceptance of the FDAMap Terms of Use and Privacy Policy.